Budget impact analysis of acalabrutinib plus venetoclax in chronic lymphocytic leukemia

Objective: To evaluate the budget impact of a fixed-duration combination (FC) “acalabrutinib + venetoclax” regimen for treatmentnaive adults with chronic lymphocytic leukemia (CLL), unmutated IGHV, and absence of del(17p) or mutations in TP53 in the Russian Federation.Material and methods. A determi...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	S. V. Nedogoda, A. S. Salasyuk, I. N. Barykina, V. O. Lutova, E. A. Popova
Fformat:	Artigo
Iaith:	Russo
Cyhoeddwyd:	IRBIS LLC 2026-05-01
Cyfres:	Фармакоэкономика
Pynciau:	chronic lymphocytic leukemia acalabrutinib venetoclax budget impact analysis bruton’s tyrosine kinase inhibitor first-line therapy
Mynediad Ar-lein:	https://www.pharmacoeconomics.ru/jour/article/view/1375
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!